Antipsychotic Medications: Enhancing Use to Improve Outcomes

Hiroyoshi Takeuchi^{1

2}, Stefan Leucht³, John M Kane^{4

5}, Ofer Agid^{2

6

7}, Gary Remington^{2

6

7

8}

Affiliations

¹ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
² Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
³ Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany.
⁴ Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY.
⁵ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY.
⁶ Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
⁷ Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
⁸ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

Editorial

Hiroyoshi Takeuchi et al. Schizophr Bull. 2021.

. 2021 Aug 21;47(5):1201-1204.

doi: 10.1093/schbul/sbab016.

Hiroyoshi Takeuchi^{1

2}, Stefan Leucht³, John M Kane^{4

5}, Ofer Agid^{2

6

7}, Gary Remington^{2

6

7

8}

¹ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
² Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
³ Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany.
⁴ Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY.
⁵ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY.
⁶ Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
⁷ Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
⁸ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

No abstract available

References

1. Howes OH, Kaar SJ. Antipsychotic drugs: challenges and future directions. World Psychiatry. 2018;17(2):170–171. - PMC - PubMed
1. Forray C, Buller R. Challenges and opportunities for the development of new antipsychotic drugs. Biochem Pharmacol. 2017;143:10–24. - PubMed
1. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014;40(2):314–326. - PMC - PubMed
1. Keepers GA, Fochtmann LJ, Anzia JM, et al. ; (Systematic Review) . The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. - PubMed
1. Galletly C, Castle D, Dark F, et al. . Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–472. - PubMed